Formulation evidence map · Published July 22, 2026 · Sources checked July 22, 2026

SculptAxis research kit overview

SculptAxis combines catalog materials associated with several different receptor systems. No cited primary study evaluated the exact kit.

Evidence boundary: ingredient studies do not establish the behavior of this exact formulation. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is SculptAxis kit?

Modified GRF(1-29), Ipamorelin, Tesamorelin, and Tirzepatide have distinct structures and evidence bases. Results cannot be pooled into a kit-level efficacy claim.

Research category
Formulations & research kits
Study models represented
Ingredient-level endocrine, receptor, animal, and clinical studies
Names in the literature
SculptAxis blend
Primary boundary
No direct evidence for combined effects, interactions, or the commercial kit.

What does the selected evidence support?

Combined-system research would require prespecified endpoints, compatibility testing, and controls for each constituent.

Primary sources

  1. Ranke et al. (1986) — GRF(1-29)-amide research; not a kit study. DOI: 10.1530/acta.0.1130276
  2. Raun et al. (1998) — Ipamorelin research; not a kit study. DOI: 10.1530/eje.0.1390552
  3. Coskun et al. (2018) — Tirzepatide research; not a kit study. DOI: 10.1016/j.molmet.2018.09.009

Ingredient evidence reviews

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review SculptAxis kit product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.